Drug Trial Radar · NCT00140621
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease
Last checked: Nov 20, 2026Latest source record: May 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Jul 2005
Primary completion
Aug 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 1, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open label, phase IV study conducted to evaluate the efficacy and safety of agalsidase beta (Fabrazyme \[recombinant form\]) administered by intravenous drip infusion in participants with cardiac Fabry disease. Participants participated for 4 weeks or less in the baseline period and 156 weeks for the treatment period.
Conditions
- Fabry Disease
Interventions
Agalsidase betaDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156Time frame: Baseline to Week 156
- Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156Time frame: Baseline to Week 156
- Percent Change From Baseline in Left Ventricular Mass (LVM) at Week 156Time frame: Baseline to Week 156
- Change From Baseline in LVM at Week 156Time frame: Baseline to Week 156
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Fujita Health University Hospital
Aichi, Japan
Sapporo Medical University Hospital
Hokkaido, Japan
Akune Citizen Hospital
Kagoshima, Japan
Tohoku University Hospital
Miyagi, Japan
Nihon University Itabashi Hospital
Tokyo, Japan
Nihon University Nerima Hikarigaoka Hospital
Tokyo, Japan
Yamanashi Prefectural Central Hospital
Yamanashi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.